CDC25 Phosphatase Inhibitor I
CAS No. 396073-89-5
CDC25 Phosphatase Inhibitor I ( BN-82002 | CDC25 Phosphatase Inhibitor I | PTP Inhibitor XX | )
产品货号. M19377 CAS No. 396073-89-5
BN82002 是 CDC25 磷酸酶的合成抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥853 | 有现货 |
|
| 10MG | ¥1169 | 有现货 |
|
| 25MG | ¥2065 | 有现货 |
|
| 50MG | ¥3460 | 有现货 |
|
| 100MG | ¥4815 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥848 | 有现货 |
|
生物学信息
-
产品名称CDC25 Phosphatase Inhibitor I
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述BN82002 是 CDC25 磷酸酶的合成抑制剂。
-
产品描述BN-82002, also known as CDC25 Phosphatase Inhibitor I, is a cell-permeable ortho-hydroxybenzylamino compound that displays anti-tumor properties. BN-82002 acts as a potent, selective, and irreversible inhibitor of CDC25 phosphatase family (IC50 = 2.4, 3.9, 6.3, 5.4, and 4.6 μM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). BN82002 inhibits the phosphatase activity of recombinant human CDC25A, B, and C in vitro. It impairs the proliferation of tumoral cell lines and increases cyclin-dependent kinase 1 inhibitory tyrosine phosphorylation. In synchronized HeLa cells, BN82002 delays cell cycle progression at G1-S, in S phase and at the G2-M transition.
-
体外实验The effect of BN82002 on cell proliferation is evaluated in vitro on several human tumor cell lines. Menadione, which has been reported to inhibit cell proliferation, is used as a control. All of the examined cell lines are sensitive to BN82002 and Menadione in a concentration-dependent manner in the low micromolar range. The most sensitive is the pancreatic cancer cell line MIA PaCa-2 with an IC50 of 7.2 μM, and the less sensitive cell line is the colon cancer HT-29 with an IC50 of 32.6 μM. The range of activity is very similar to the one observed with menadione (5-15 μM). It is also showed that 50 μM BN82002 is a concentration that fully inhibits cell proliferation, the cell cycle distribution is only modestly affected with a slight decrease in S phase and an increase in cells containing both a G1 and a G2 DNA content, suggesting that the cells treated with BN82002 are arrested at various stages of the cell cycle.
-
体内实验——
-
同义词BN-82002 | CDC25 Phosphatase Inhibitor I | PTP Inhibitor XX |
-
通路Metabolic Enzyme/Protease
-
靶点Phosphatase
-
受体CDC25A|CDC25B2|CDC25B3|CDC25C|CDC25C-cat
-
研究领域——
-
适应症——
化学信息
-
CAS Number396073-89-5
-
分子量359.42
-
分子式C19H25N3O4
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 150 mg/mL; 417.34 mM
-
SMILESOc1c(cc(cc1OC)N(C)C)CN(C)CCc2ccc(cc2)[N+]([O-])=O
-
化学全称Phenol, 4-(dimethylamino)-2-methoxy-6-((methyl(2-(4-nitrophenyl)ethyl)amino)methyl)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Brezak MC, et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res. 2004 May 1;64(9):3320-5.
产品手册
关联产品
-
BPDA2
BPDA2 是一种高选择性和竞争性活性位点 SHP2 抑制剂,对 SHP2、SHP1、SHP1B 的 IC50 分别为 92.0 nM、33.39 μM、40.71 μM。DBDA2 下调促有丝分裂、细胞存活信号和 RTK 表达。BPDA2 抑制 SHP2 介导的信号转导和乳腺癌细胞表型。
-
SHP099
SHP099 游离碱是一种有效的、选择性的、口服生物可利用的、有效的 SHP2 抑制剂(IC50 = 0.07 μM,细胞中的 p-ERK 调节 IC50 = 0.250 μM)。 SHP099 在异种移植模型中显示出剂量依赖性途径抑制和抗肿瘤活性。
-
Ertiprotafib
Ertiprotafib 是 PTP1B, IKK-β 的抑制剂,其 IC50 值分别是 1.6 μM,400 nM,同时也是PPARα/PPARβ 的激动剂,其 EC50 值为 ~1 μM。
021-51111890
购物车()
sales@molnova.cn

